Skip to main content

DNA methylation patterns of β-globin cluster in β-thalassemia patients

Abstract

Background

Reactivation of fetal hemoglobin (HbF, α2γ2) holds a therapeutic target for β-thalassemia and sickle cell disease. Although many HbF regulators have been identified, the methylation patterns in β-globin cluster driving the fetal-to-adult hemoglobin switch remains to be determined.

Results

Here, we evaluated DNA methylation patterns of the β-globin cluster from peripheral bloods of 105 β00 thalassemia patients and 44 normal controls. We also recruited 15 bone marrows and 4 cord blood samples for further evaluation. We identified that the CpG sites in the locus control region (LCR) DNase I hypersensitive site 4 and 3 (HS4-3) regions, and γ- and β-globin promoters displayed hypomethylation in β00-thalassemia patients, especially for the patients with high HbF level, as compared with normal controls. Furthermore, hypomethylations in most of CpG sites of the HS4-3 core regions were also observed in bone marrows (BM) of β00-patients compared with normal controls; and methylation level of γ-globin promoter -50 and + 17 CpG sites showed lower methylation level in patients with high HbF level compared with those with low HbF level and a negative correlation with HbF level among β0-thalassemia patients. Finally, γ-globin promoter + 17 and + 50 CpG sites also displayed significant hypomethylation in cord blood (CB) tissues compared with BM tissues from normal controls.

Conclusions

Our findings revealed methylation patterns in β-globin cluster associated with β0 thalassemia disease and γ-globin expression, contributed to understand the epigenetic modification in β0 thalassemia patients and provided candidate targets for the therapies of β-hemoglobinopathies.

Background

The human β-globin cluster, spanning a 70-kb region, is composed of five genes (5′-HBE -HBG2 -HBG1 -HBD -HBB-3′; 5′-ε-γGA-δ-β-3′) and a distal regulatory element known as LCR [1], which plays an important role in regulating the expression of all the genes in the cluster. β-thalassemia is characterized by a quantitative defect in the synthesis of β-globin chains underlaid by a marked genotypic heterogeneity of β-globin gene mutations. Reactivating of HbF was reported to be a therapeutic target for β-thalassemia and SCD. Several genetic modulators [2,3,4,5,6,7] and cis-regulatory elements [6, 8,9,10,11,12] involved in the regulation of human fetal hemoglobin (HbF), and concomitant α-thalassemia have been identified as ameliorators of β-thalassemia [13]. DNA methyltransferase (DNMT) inhibitor 5-azacytidine (5-aza) has been applied to hemoglobinopathy patients (mainly in SCD patients) through improvement of HbF expression in the 1980s and 1990s [14, 15], which supported that DNA methylation plays an important role in human globin switching. In 2007, Rodwell Mabaera et al. used three human fetal liver and three BM samples, respectively, to reveal the changes of DNA methylation in β- and γ-globin promoters during fetal-adult globin switching, and proved the negative correlation between promoters DNA methylation level and expression of globin genes in human development stage [16]. Mei Hsu et al. have analyzed the methylation status of regions in the murine β-like globin locus in uncultured primitive and definitive erythroblasts and other cultured primary and transformed cell types [17]. They found a 20-kb domain, extended from the region just past the LCR to before β-major and encompassed the embryonic genes εy, βh1, and βh0, is hypomethylated only in primitive erythroid cells. Even retrotransposons in this region are hypomethylated in primitive erythroid cells.

Although epigenetic-based underlying mechanism driving the fetal-to-adult hemoglobin switch have been studied and reported in mouse and human, the systematic scanning of methylation patterns in β-globin cluster remains to be determined, especially in β-thalassemia patients. Here, we uncovered the methylation patterns of β-globin cluster, and explored its roles in regulating HbF gene expression in PB, BM, or CB samples from human β-thalassemia patients or normal controls.

Results

To evaluate the methylation status of the β-globin clusters in β-thalassemia patients, we first screened the methylation patterns of total 97 CpG sites on the β-globin cluster, including ε-, γ-, δ-, and β-globin promoters, the core sequences of HS4 and HS3 and the 5′ flanking sequences of the LCR region, the CpGs-rich region of the HS2-HS1 intergenic region, the CpG islands (CpGI) in the endogenous retrovirus 9 (ERV-9) located at upstream of HS5, and the predicted binding region of the transcription factor BCL11A on the gene cluster located about 3.5 kb upstream of δ-globin gene [9] (Fig. 1a), in PB of 105 β00 thalassemia patients and 44 normal controls using bisulfite sequencing method as previously described [12]. We observed that most of CpG sites around the LCR HS4-HS3 regions, and γ- and β-globin promoter displayed significant hypomethylation in β00-thalassemia patients compared with normal controls (Fig. 1b, shown with stars under indicated sites), especially for the TFH patients (Fig. 1c). We didn’t find any significant differences in methylation level in the other examined regions among the three indicated groups (data not shown). Since DNA methylation can be associated with aging progression and significant differences in age between β-thalassemia patients and normal controls, we then included age as a covariate in analysis of covariance (ANCOVA) of methylation difference between β-thalassemia patients and normal controls and observed that hypomethylation in β-thalassemia patients remained significance in most of CpG sites around the LCR HS4 region, and γ- and β-globin promoters (Fig. 1b, shown with stars above indicated sites). We further divided the β00 thalassemia patients into two subgroups: subjects with age < 5 years old (Fig. 1d) and subjects with 5–15 years old (Fig. 1e), and observed that the TFH patients still displayed significant lower methylation levels than the TFL patients, especially for the subjects with 5–15 years old (Fig. 1e).

Fig. 1
figure1

Methylation patterns of β-globin cluster in PB tissues. a Schematic of β-globin cluster. The dashed box showed the target regions in DNA methylation examination. b Methylation differences in β0-thalasssmia patients from normal controls (CON) were shown with *p < 0.05, **p < 0.01, ***p < 0.001 in ANCOVA analysis without (under indicated sites) or with (above indicated sites) age covariate. c Methylation level relative to CON (the horizontal dashed line) in TFL (black) or TFH (gray) patients are represented by scatter plot for each CpG site with standard error indicated by bars. *p < 0.05, **p < 0.01, ***p < 0.001 indicated the significant difference in the TFH and/or TFL patients from CON. d, e Methylation pattern between the TFH and TFL patients with age < 5 years (d) and age within 5–15 years (e). #p < 0.05, ##p < 0.01, ###p < 0.001 indicated significant difference from t test between the TFH and THL group in panels of c to e. Five CpG sites (2631 for site 1, 2753 for 2, 2786 for 3, 2868 for HS4-1 and 2928 for HS4-2 relative to the first nucleotide of LCR (chr11:5275850, hg38)) around HS4, five CpG sites (5808 for 1, 5860 for 2, 5943 for 3, 6093 for 4 and 6164 for HS3-1 relative to the first nucleotide of LCR) around HS3, six CpG sites (− 162, − 53, − 50, + 6, + 17 and + 50 relative to the transcriptional start site of γ-globin gene) in the γ-promoter and five CpG sites (− 415, − 307, − 266, − 126 and + 83 relative to the transcriptional start site of β-globin gene) in the β-promoter are shown under each column in panel e  

Given that DNA in PB mainly derived from the lymphocyte cells, which will have some limitations for DNA methylation research with high tissue heterogeneity, we then examined DNA methylation in BM GYPA (Glycophorin A) positive cells and observed that significant hypomethylation at most of CpG sites in core regions of HS4-HS3 and the 5′ flanking sequences, especially in the HS4 region, in β00-patients compared with the normal controls (Fig. 2a). Moreover, we observed that the TFH patients showed significant lower methylation level at the − 50 and + 17 CpG sites of γ-globin promoter than both the TFL patients and normal controls (Fig. 2b). We did not observe any significant differences in β-globin promoter between β00-patients and normal controls. Furthermore, we employed bisulfite clone method to validate methylation pattern of γ-globin promoter in β00-thalassemia patients and normal controls, and observed that hypomethylation at − 50, + 17, and + 50 CpG sites of γ-globin promoter in the TFH patients compared with the TFL patients and normal controls (Fig. 2c).

Fig. 2
figure2

Methylation patterns of β-globin cluster in BM tissues. a Methylation differences in β-thalassemia patients from CON were shown with *p < 0.05, **p < 0.01 and ***p < 0.001 from t-test. b Methylation level relative to CON (the horizontal dashed line) in TFL (black) or TFH (gray) patients are represented by scatter plot for each CpG site with standard error indicated by bars. *p < 0.05, **p < 0.01, ***p < 0.001 indicated the significant difference in TFH and/or TFL from CON. ###p < 0.001 indicated significant difference between TFH and THL group. c Methylation levels at CpG sites in HBG promoter verified by bisulfite-treated clone sequencing. methylated CpGs; unmethylated CpGs. Count, the numbers of the same clone

To further verify the relationship of the methylation status of γ-globin promoter with the HbF level, we performed Pearson correlation analysis of γ-promoter methylation level with HbF level in BM tissues from nine β00-patients and observed that γ-globin promoter—50 (r2 = 0.49, p = 0.03) and + 17 (r2 = 0.91, p < 0.001) CpG sites displayed significantly negative correlations with the HbF level (Fig. 3). More importantly, we observed that γ-globin promoter + 17 and + 50 CpG sites displayed significant hypomethylation in CB tissues compared with BM tissues of normal controls, which is consistent with a higher HbF expression level in CB (HbF: 76.2 ± 7.9%; Fig. 4) than in BM (HbF: 0.3 ± 0.1%). Altogether, these results indicated that the methylation level of LCR HS4-3 regions was associated with thalassemia, and the methylation level of γ-globin promoter was associated with HbF expression.

Fig. 3
figure3

Relationship between γ-globin promoter DNA methylation level and HbF level. Relationships between γ-globin promoter − 50, + 17, and + 50 CpG sites DNA methylation level and HbF level in BM tissues of nine β00-patients were represented by lines shown with correlation coefficient r2 and p value

Fig. 4
figure4

DNA methylation patterns in CM and BM tissues. Methylation levels of the indicated CpG sites in the LCR 5′HS4 and the cord region of HS4 (a), 5′HS3 and the cord region of HS3 (b), γ-globin promoter (c), and β-globin promoter (d) between CB tissue (grey) and BM (black) tissues of normal controls are shown in columns with standard error indicated by bars. #p < 0.05 from two-tailed t-test

Discussion

In this study, we found that the hypomethylation in LCR regions, especially the HS4-3 core regions, was correlated with thalassemia; the methylation level of + 17 CpG site in γ-globin promoter was negatively correlated with HbF expression level, providing an important role of methylation in regulating globin expression in different developmental stage.

It is important to uncover the methylation patterns that account for phenotypic manifestation and HbF expression in β-thalassemia. A previously study has uncovered the methylation patterns in CD34+ primary cells from fetal liver and BM of healthy donors [18]. They found that several differentially methylated CpGs are located near genes with unanticipated roles in red blood cell differentiation and proliferation, and a correlation between the γ-globin promoter DNA methylation and HbF levels in red blood cell progenitors, which was consistent with our results that observed in BM. Some researchers also discovered dynamic DNA methylation of γ-globin promoter in mouse uncultured primitive, definitive erythroblasts, and other cultured primary and transformed cell types, supporting a mechanistic role for DNA methylation in developmental regulation of globin genes [17]. This dynamic DNA methylation pattern was further observed in our study that γ-globin promoter methylation was higher in BM than in CB tissue, elucidating the negative relationship between γ-globin promoter methylation and gene expression with developmental stage.

We further found that the methylation patterns in LCR regions from PB tissue were mostly hypomethylated in β00-thalassemia patients, which was consistent with the case-controls difference patterns observed in BM tissue. However, we found the methylation patterns in γ- globin promoter showed difference between TFH and TFL group of β-thalassemia. The methylation level of most CpG sites in γ-globin promoter were hypomethylated, especially in + 17 and + 50 sites, in the BM tissues of TFH patients, compared with TFL patients, which was consistent with our previous report [12]. The γ-globin promoter methylation, not LCR region DNA methylation, might be the main effect to γ-globin expression, and the methylation alteration in the γ-globin promoter may be a driving factor leading to remote regulation between globin promoter and LCR regions [19]. The hypomethylated patterns in globin promoters might make it easier to access for some transcription factors mediating the looping with globin promoter. In fact, our previous study showed that a SNP rs368698783 was associated with the methylation level on + 17 CpG site in γ-globin promoter [12], by recruiting DNMT3A to the promoter and further regulating the γ-globin expression, supporting the important role of γ-globin promoter methylation in regulation of γ-globin expression.

Since only 15 BM subjects employed in this study to obtain methylation alterations in LCR regions associated with β0-thalassemia and in γ-globin promoter associated with HbF expression level, it will require larger samples from BM tissues to further verify these results. In addition, given the limitation of ethic approval, we have no evaluated the patterns in fetal liver, which would give a more comprehensive view of the methylation patterns in different developmental stage. Finally, effect of methylation alterations at γ-globin promoter + 17 CpG site on the HbF level should be examined by using site-specific methylation through dCas9-MQ1-sgRNA system in further study.

Conclusion

Our findings revealed methylation patterns in β-globin cluster associated with β0 thalassemia disease or γ-globin expression, contributed to understand the epigenetic modification in β0 thalassemia patients and provided candidate targets for the therapies of β-hemoglobinopathies.

Methods

Human subjects

We recruited 105 subjects with β00-thalassemia from southern China. These 105 unrelated Chinese β-thalassemia patients with a large range of HbF expression levels were stratified into low- and high-HbF groups for this study: 52 cases of high HbF (TFH, HbF: 58.9 ± 19.8%) and 53 cases of low HbF (TFL, HbF: 2.0 ± 0.7%). A subset of 44 healthy adult controls (CON, HbF: 0.3 ± 0.2%) was selected from a large random Guangxi population screened as the previously mentioned [20] (Additional file 1: Tables S1 and S2). DNA extracted from peripheral blood lymphocyte (PB) of above 105 β00 thalassemia patients and 44 healthy donors were used for DNA methylation analysis. Moreover, DNA extracted from GYPA (Glycophorin A) positive cells separated from bone marrows (BM) of nine β00 thalassemia patients including six TFL β00-patients (HbF: 7.46 ± 5.28 g/L) and three TFH β00-patients (HbF: 95.39 ± 9.69 g/L) and six healthy adult controls (HbF: 0.37 ± 0.05 g/L), eight of which were also used in our previous study [12], and from CB (HbF: 76.2 ± 7.9%) of four healthy adult controls were used for examination of the methylation patterns in different tissues.

Hematological parameters were measured using an automated hematology analyzer (Sysmex F-820; Sysmex Co. Ltd., Kobe, JP). Adult and fetal hemoglobin analysis was carried out using high-performance liquid chromatography (Variant II, Bio-Rad Laboratories, Hercules, CA). DNA was extracted DNA by Phenol–chloroform method. We used XmnI PCR-restriction fragment length polymorphism (RFLP) and high-resolution melting (HRM) assays to genotype KLF1 mutations and three primary HbF-associated single nucleotide polymorphisms (rs7482144, XmnI, in HBG2, rs766432 in BCL11A, and rs9399137 in HBS1L-MYB) as described [4, 12] to unified genetic variants between TFH and TFL group. The study protocol was reviewed and approved by the local medical ethics committee at Nanfang Hospital, China, and conducted in accordance with the Declaration of Helsinki.

DNA methylation assay

We used bisulfite conversion method to examine DNA methylation as previously described [12]. Bisulfite conversion of DNA was performed by denaturing 1 mg genomic DNA with 0.3 M NaOH at 42℃ for 20 min, followed by 95℃ for 3 min and 0℃ for 1 min, and incubating at pH 5.0 with sodium metabisulfite (2.0 M) and hydroquinone (0.5 mM) at 55℃ for 16 h in the dark overlaid with mineral oil. Modified DNA was purified with Promega Wizard DNA Clean Up System (Madison, WI, USA). The eluted DNA was incubated with NaOH (0.3 M) at 37℃ for 15 min and neutralized by 3 M NH4-acetate to pH 7.0. The neutralized DNA was precipitated by 75% ethanol and recovered in 20 ml of TE buffer. We used nested-PCR to amplify the target DNA regions and performed Sanger sequencing. Because unmethylated cytosine (C) was replaced by thymine (T) after PCR reaction, any presence of C at CpG dinucleotides on the sequence represented a methylated C allele in the bisulfite-modified DNA. The percentage methylation of CpG sites was determined based on the C and T allele peaks by means of BioEdit Sequence Alignment Editor v7.0.9.0 (Carlsbad, CA, USA). We further performed bisulfite-treated clone sequencing assay to verify DNA methylation patterns examined by Sanger sequencing. In brief, we cloned BS-PCR products of bisulfite-DNA into the pMD19T cloning vector (D104, TAKARA, Japan), and sequenced 22 clones to calculate the percentage of C as methylation% for each subject. The primers used in this study are listed in Additional file 1: Table S3.

Statistical analysis

A two-tailed student t-test from SPSS v20 software was used for comparisons between the two indicated groups in this study. ANCOVA analysis with age as a covariate was also used in case–control analysis of methylation difference. P values of < 0.05 were considered as statistically significant.

Availability of data and materials

All the data in this study were available in the figures and tables in the manuscript.

Abbreviations

HbF:

Fetal hemoglobin

PB:

Peripheral bloods

BM:

Bone marrow

SCD:

Sickle cell disease

LCR:

Locus control region

HS4-3:

Hypersensitive site 4 and 3

DNMT:

DNA methyltransferase

5-aza:

5-Azacytidine

CpGI:

CpG islands

ERV-9:

Endogenous retrovirus 9

Glycophorin A:

GYPA

CB:

Cord blood

RFLP:

Fragment length polymorphism

HRM:

High-resolution melting

References

  1. 1.

    Levings PP, Bungert J. The human beta-globin locus control region. J Eur J Biochem. 2002;269:1589–99.

    CAS  Article  Google Scholar 

  2. 2.

    Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. J Science. 2008;322:1839–42.

    CAS  Google Scholar 

  3. 3.

    Zhou D, Liu K, Sun CW, et al. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. J Nat Genet. 2010;42:742–4.

    CAS  Article  Google Scholar 

  4. 4.

    Liu D, Zhang X, Yu L, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of beta-thalassemia. J Blood. 2014;124:803–11.

    CAS  Article  Google Scholar 

  5. 5.

    Stadhouders R, Aktuna S, Thongjuea S, et al. HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. J J Clin Invest. 2014;124:1699–710.

    CAS  Article  Google Scholar 

  6. 6.

    Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. J Science. 2013;342:253–7.

    CAS  Google Scholar 

  7. 7.

    Grevet JD, Lan XJ, Hamagami N, et al. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. J Science. 2018;361:285.

    CAS  Google Scholar 

  8. 8.

    Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. J Proc Natl Acad Sci USA. 2008;105:11869–74.

    CAS  Article  Google Scholar 

  9. 9.

    Sankaran VG, Xu J, Byron R, et al. A functional element necessary for fetal hemoglobin silencing. J N Engl J Med. 2011;365:807–14.

    CAS  Article  Google Scholar 

  10. 10.

    Farrell JJ, Sherva RM, Chen ZY, et al. A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. J Blood. 2011;117:4935–45.

    CAS  Article  Google Scholar 

  11. 11.

    Gilman JG, Huisman TH. DNA sequence variation associated with elevated fetal G gamma globin production. J Blood. 1985;66:783–7.

    CAS  Article  Google Scholar 

  12. 12.

    Chen DY, Zuo YJ, Zhang XH, et al. A genetic variant ameliorates beta-thalassemia severity by epigenetic-mediated elevation of human fetal hemoglobin expression. J Am J Hum Genet. 2017;101:130–8.

    CAS  Article  Google Scholar 

  13. 13.

    Mettananda S, Gibbons RJ, Higgs DR. α-Globin as a molecular target in the treatment of beta-thalassemia. J Blood. 2015;125:3694–701.

    CAS  Article  Google Scholar 

  14. 14.

    Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. J N Engl J Med. 1982;307:1469–75.

    CAS  Article  Google Scholar 

  15. 15.

    Lowrey CH, Nienhuis AW. Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. J N Engl J Med. 1993;329:845–8.

    CAS  Article  Google Scholar 

  16. 16.

    Mabaera R, Richardson CA, Johnson K, et al. Developmental- and differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation. J Blood. 2007;110:1343–52.

    CAS  Article  Google Scholar 

  17. 17.

    Hsu M, Mabaera R, Lowrey CH, et al. CpG hypomethylation in a large domain encompassing the embryonic beta-like globin genes in primitive erythrocytes. J Mol Cell Biol. 2007;27:5047–54.

    CAS  Article  Google Scholar 

  18. 18.

    Lessard S, Beaudoin M, Benkirane K, et al. Comparison of DNA methylation profiles in human fetal and adult red blood cell progenitors. J Genome Med. 2015;7:1.

    Article  Google Scholar 

  19. 19.

    Deng W, Rupon JW, Krivega I, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. J Cell. 2014;158:849–60.

    CAS  Article  Google Scholar 

  20. 20.

    Xiong F, Sun M, Zhang X, et al. Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern China. J Clin Genet. 2010;78:139–48.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank the patients for their willingness to participate in this study. Prof. Xiangmin Xu for valuable suggestion and Dr. Xinhua Zhang for helping to recruit the participates.

Funding

This study was financial supports by the Guangdong Science and Technology Foundation (Grant No. 2019B030316032).

Author information

Affiliations

Authors

Contributions

Conceived and designed the experiments: XB, YZ, DC and CZ. Performed the experiments: XB, YZ and DC. Analyzed the data: YZ and XB. Collected and diagnosed the subjects: YZ and DC. Wrote the paper: XB, YZ and CZ. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Cunyou Zhao.

Ethics declarations

Ethics approval and consent to participate

Informed consent was obtained from all the patients in this study. The study protocol was reviewed and approved by the local medical ethics committee at Nanfang Hospital, China, and conducted in accordance with the Declaration of Helsinki.

Consent for publication

The authors of the manuscript have read and agreed to the consent for publication.

Competing interests

The authors declare no competing financial interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1:

Phenotypic data of human subjects (Tables S1 and S2) and sequences of primers (Table S3) employed in this study.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bao, X., Zuo, Y., Chen, D. et al. DNA methylation patterns of β-globin cluster in β-thalassemia patients. Clin Epigenet 12, 187 (2020). https://doi.org/10.1186/s13148-020-00987-2

Download citation

Keywords

  • β0 thalassemia patients
  • β-globin cluster
  • Fetal hemoglobin
  • Methylation patterns
  • Bone marrow
  • Cord blood
  • Developmental stage